SOURCE: Prana Biotechnology

December 11, 2007 12:09 ET

Prana Co-Founding Scientist, Professor Rudolph Tanzi, to Present at Credit Suisse Conference

Expert Panel Discussion to Address "The Amyloid Hypotheses of Alzheimer's Disease"

MELBOURNE, AUSTRALIA--(Marketwire - December 11, 2007) - Prana Biotechnology Limited (NASDAQ: PRAN) (ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, today announced that Rudolph E. Tanzi, Ph.D., Co-Founding Scientist of Prana Biotechnology, is scheduled to present "The Amyloid Hypotheses of Alzheimer's Disease," an expert panel on Alzheimer's Disease hosted by Credit Suisse Conference on December 14, 2007 at 10:00 a.m.

Prana co-founding scientists' theories concerning the interaction between metals and the protein beta-amyloid in the brain are the basis of Prana's treatments for Alzheimer's and other neurodegenerative diseases. Prana's proprietary lead compound, PBT2, is currently in a Phase IIa clinical trial for patients with early Alzheimer's disease. The trial is progressing well, with patient dosing on track to be completed by the end of 2007.

For further details of the Conference and presentation, visit the Prana Biotechnology website

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related neurodegenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

For further information, please visit our web site at

Contact Information